Novartis Fights Alexion's Soliris Patent

Law360, New York (August 19, 2010, 1:19 PM EDT) -- Alexion Pharmaceuticals Inc. revealed Thursday that Swiss drug giant Novartis AG had launched a challenge to Alexion's European patent for blood disorder treatment Soliris.

In a regulatory filing with the U.S. Securities and Exchange Commission, Alexion said Novartis' opposition to the patent had been filed with the European Patent Office on Wednesday.

The patent, EP 0758904, is currently valid in 14 countries in the European Union, including France, Germany, Italy, Spain, and the United Kingdom, and expires May 1, 2015, the filing said.

Soliris, also known...
To view the full article, register now.